Orforglipron vs Semaglutide: oral vs injectable
Comparing 2 compounds by evidence grade, FDA status, mechanism, and key safety considerations: Orforglipron, Semaglutide.
| Orforglipron | Semaglutide | |
|---|---|---|
| Evidence grade | Grade A: Approved and proven | Grade A: Approved and proven |
| FDA status | FDA approved FDA-approved April 1, 2026, for obesity (BMI at least 30 kg/m²) or overweight (BMI at least 27 kg/m²) with at least one weight-related comorbidity. | FDA approved Approved as Ozempic (subcutaneous injection, type 2 diabetes), Wegovy (subcutaneous injection 2.4 mg and oral 25 mg tablet, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral tablet, type 2 diabetes). |
| Mechanism | Non-peptide small molecule that selectively activates the GLP-1 receptor, suppressing appetite through central and peripheral pathways, slowing gastric emptying, and enhancing glucose-dependent insulin secretion. | Semaglutide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral GLP-1 receptor activation. |
| Key safety | Foundayo carries an FDA boxed warning for thyroid C-cell tumors: GLP-1 receptor agonists pharmacologically active in rodents have caused thyroid C-cell adenomas... | Boxed warning: semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures; human relevance is unknown but it is contraindicated in pat... |